Phase II trial for patients with newly diagnosed glioblastoma (GBM) treated with carmustine wafers followed by concurrent radiation therapy (RT), temozolomide (TMZ), and bevacizumab (BV), then followed by TMZ and BV post-RT.
Publication
, Conference
Ranjan, T; Peters, KB; Vlahovic, G; Alderson, LM; Herndon, JE; McSherry, F; Threatt, S; Sampson, JH; Friedman, AH; Bigner, DD; Friedman, HS ...
Published in: JOURNAL OF CLINICAL ONCOLOGY
May 20, 2013
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2013
Volume
31
Issue
15
Location
Chicago, IL
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Ranjan, T., Peters, K. B., Vlahovic, G., Alderson, L. M., Herndon, J. E., McSherry, F., … Desjardins, A. (2013). Phase II trial for patients with newly diagnosed glioblastoma (GBM) treated with carmustine wafers followed by concurrent radiation therapy (RT), temozolomide (TMZ), and bevacizumab (BV), then followed by TMZ and BV post-RT. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 31). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
Ranjan, Tulika, Katherine B. Peters, Gordana Vlahovic, Lloyd M. Alderson, James Emmett Herndon, Frances McSherry, Stevie Threatt, et al. “Phase II trial for patients with newly diagnosed glioblastoma (GBM) treated with carmustine wafers followed by concurrent radiation therapy (RT), temozolomide (TMZ), and bevacizumab (BV), then followed by TMZ and BV post-RT.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 31. AMER SOC CLINICAL ONCOLOGY, 2013.
Ranjan T, Peters KB, Vlahovic G, Alderson LM, Herndon JE, McSherry F, et al. Phase II trial for patients with newly diagnosed glioblastoma (GBM) treated with carmustine wafers followed by concurrent radiation therapy (RT), temozolomide (TMZ), and bevacizumab (BV), then followed by TMZ and BV post-RT. In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2013.
Ranjan, Tulika, et al. “Phase II trial for patients with newly diagnosed glioblastoma (GBM) treated with carmustine wafers followed by concurrent radiation therapy (RT), temozolomide (TMZ), and bevacizumab (BV), then followed by TMZ and BV post-RT.” JOURNAL OF CLINICAL ONCOLOGY, vol. 31, no. 15, AMER SOC CLINICAL ONCOLOGY, 2013.
Ranjan T, Peters KB, Vlahovic G, Alderson LM, Herndon JE, McSherry F, Threatt S, Sampson JH, Friedman AH, Bigner DD, Friedman HS, Vredenburgh JJ, Desjardins A. Phase II trial for patients with newly diagnosed glioblastoma (GBM) treated with carmustine wafers followed by concurrent radiation therapy (RT), temozolomide (TMZ), and bevacizumab (BV), then followed by TMZ and BV post-RT. JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2013.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2013
Volume
31
Issue
15
Location
Chicago, IL
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences